James Lu

Mark Laurie, James Lu

While tumor dynamic modeling has been widely applied to support the development of oncology drugs, there remains a need to increase predictivity, enable personalized therapy, and improve decision-making. We propose the use of Tumor Dynamic Neural-ODE (TDNODE) as a pharmacology-informed neural network to enable model discovery from longitudinal tumor size data. We show that TDNODE overcomes a key limitation of existing models in its ability to make unbiased predictions from truncated data. The encoder-decoder architecture is designed to express an underlying dynamical law which possesses the fundamental property of generalized homogeneity with respect to time. Thus, the modeling formalism enables the encoder output to be interpreted as kinetic rate metrics, with inverse time as the physical unit. We show that the generated metrics can be used to predict patients' overall survival (OS) with high accuracy. The proposed modeling formalism provides a principled way to integrate multimodal dynamical datasets in oncology disease modeling.

Omid Bazgir, Zichen Wang, Ji Won Park et al.

In anti-cancer drug development, a major scientific challenge is disentangling the complex relationships between high-dimensional genomics data from patient tumor samples, the corresponding tumor's organ of origin, the drug targets associated with given treatments and the resulting treatment response. Furthermore, to realize the aspirations of precision medicine in identifying and adjusting treatments for patients depending on the therapeutic response, there is a need for building tumor dynamic models that can integrate both longitudinal tumor size as well as multimodal, high-content data. In this work, we take a step towards enhancing personalized tumor dynamic predictions by proposing a heterogeneous graph encoder that utilizes a bipartite Graph Convolutional Neural network (GCN) combined with Neural Ordinary Differential Equations (Neural-ODEs). We applied the methodology to a large collection of patient-derived xenograft (PDX) data, spanning a wide variety of treatments (as well as their combinations) on tumors that originated from a number of different organs. We first show that the methodology is able to discover a tumor dynamic model that significantly improves upon an empirical model which is in current use. Additionally, we show that the graph encoder is able to effectively utilize multimodal data to enhance tumor predictions. Our findings indicate that the methodology holds significant promise and offers potential applications in pre-clinical settings.

Ruiyu Wang, Yuzhang Xie, Xiao Hu et al.

Assessing journal impact is central to scholarly communication, yet existing open resources rarely capture how collaboration structures and artificial intelligence (AI) research jointly shape venue prestige in biomedicine. We present BioMedJImpact, a large-scale, biomedical-oriented dataset designed to advance journal-level analysis of scientific impact and AI engagement. Built from 1.74 million PubMed Central articles across 2,744 journals, BioMedJImpact integrates bibliometric indicators, collaboration features, and LLM-derived semantic indicators for AI engagement. Specifically, the AI engagement feature is extracted through a reproducible three-stage LLM pipeline that we propose. Using this dataset, we analyze how collaboration intensity and AI engagement jointly influence scientific impact across pre- and post-pandemic periods (2016-2019, 2020-2023). Two consistent trends emerge: journals with higher collaboration intensity, particularly those with larger and more diverse author teams, tend to achieve greater citation impact, and AI engagement has become an increasingly strong correlate of journal prestige, especially in quartile rankings. To further validate the three-stage LLM pipeline we proposed for deriving the AI engagement feature, we conduct human evaluation, confirming substantial agreement in AI relevance detection and consistent subfield classification. Together, these contributions demonstrate that BioMedJImpact serves as both a comprehensive dataset capturing the intersection of biomedicine and AI, and a validated methodological framework enabling scalable, content-aware scientometric analysis of scientific impact and innovation dynamics. Code is available at https://github.com/JonathanWry/BioMedJImpact.

Samira Pakravan, Nikolaos Evangelou, Maxime Usdin et al.

Digital health technologies (DHT), such as wearable devices, provide personalized, continuous, and real-time monitoring of patient. These technologies are contributing to the development of novel therapies and personalized medicine. Gaining insight from these technologies requires appropriate modeling techniques to capture clinically-relevant changes in disease state. The data generated from these devices is characterized by being stochastic in nature, may have missing elements, and exhibits considerable inter-individual variability - thereby making it difficult to analyze using traditional longitudinal modeling techniques. We present a novel pharmacology-informed neural stochastic differential equation (SDE) model capable of addressing these challenges. Using synthetic data, we demonstrate that our approach is effective in identifying treatment effects and learning causal relationships from stochastic data, thereby enabling counterfactual simulation.

James Lu, Brendan Bender, Jin Y. Jin et al.

The longitudinal analysis of patient response time course following doses of therapeutics is currently performed using Pharmacokinetic/Pharmacodynamic (PK/PD) methodologies, which requires significant human experience and expertise in the modeling of dynamical systems. By utilizing recent advancements in deep learning, we show that the governing differential equations can be learnt directly from longitudinal patient data. In particular, we propose a novel neural-PK/PD framework that combines key pharmacological principles with neural ordinary differential equations. We applied it to an analysis of drug concentration and platelet response from a clinical dataset consisting of over 600 patients. We show that the neural-PK/PD model improves upon a state-of-the-art model with respect to metrics for temporal prediction. Furthermore, by incorporating key PK/PD concepts into its architecture, the model can generalize and enable the simulations of patient responses to untested dosing regimens. These results demonstrate the potential of neural-PK/PD for automated predictive analytics of patient response time course.